ASND vs. SNY: Ascendis Pharma vs. Sanofi Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Ascendis Pharma (ASND) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Ascendis Pharma (ASND) at 118.78% clears its industry range for ROE, a sharper capital-efficiency signal than Sanofi (SNY) at 5.72%, which is closer to a typical peer reading.

Ascendis Pharma (ASND) at 70.85% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

Both Ascendis Pharma (ASND) at 64.98% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Sanofi (SNY) at 5.49% is closer to the peer norm — faster top-line expansion for ASND.

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Both Ascendis Pharma (ASND) at 0.31 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Ascendis Pharma (ASND) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Ascendis Pharma (ASND) at 19.68 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Ascendis Pharma (ASND) at 16.14 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Ascendis Pharma (ASND) at 10.45 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics